CHA2DS2-VASc score in acute ischemic stroke with atrial fibrillation: results from the Clinical Research Collaboration for Stroke in Korea

Table 3 Association of CHA2DS2-VASc scores with primary outcomes in the OAC treatment group (n = 5500).

	Crude HR (95% CI)	P	Model 1 (HR, 95% CI)	P	Model 2 (HR, 95% CI)	P
Per 1-point increase	1.31 (1.25–1.38)	< 0.001	1.19 (1.12–1.25)	< 0.001	1.21 (1.14–1.28)	< 0.001
0	Ref		Ref		Ref
1	1.28 (0.47–3.48)	0.63	1.06 (0.39–2.89)	0.91	1.17 (0.43–3.20)	0.76
2	3.60 (1.45–8.93)	0.01	2.22 (0.89–5.53)	0.09	2.57 (1.03–6.43)	0.04
3	4.58 (1.87–11.23)	0.001	2.36 (0.95–5.84)	0.06	2.79 (1.12–6.95)	0.03
4	5.66 (2.32–13.82)	0.0001	2.61 (1.05–6.45)	0.04	3.25 (1.30–8.09)	0.01
5	7.48 (3.06–18.29)	< 0.001	3.35 (1.35–8.30)	0.01	4.25 (1.70–10.64)	0.002
6	9.16 (3.71–22.62)	< 0.001	3.91 (1.56–9.82)	0.004	4.81 (1.90–12.18)	0.001
7 or more	10.45 (4.13–26.45)	< 0.001	4.08 (1.58–10.51)	0.004	5.34 (2.05–13.94)	0.001

Model 1: age, initial NIHSS, prior anticoagulation.
Mode 2: age, initial NIHSS, BMI, arrival time, dyslipidemia, smoking, prior anticoagulation, prior statin, antihypertensive treatment, antidiabetic treatment, statin treatment, reperfusion therapy, creatinine, glucose, SBP, large artery diseases, multiple lesions, stroke mechanism (TOAST).